Treatment Strategies for Heroin and Opioid Addiction

Introduction

This paper examines research on treatment strategies for heroin and opioid addiction, with a focus on three specific approaches: antagonist therapy, aversive therapy, and anti-drug vaccine research.

Antagonist therapy is a type of treatment for heroin addiction that works by blocking the effects of the drug. It is typically used in conjunction with other forms of treatment, such as counseling and behavioral therapy. There are two main types of antagonists: natural and synthetic. Natural antagonists, such as naltrexone, bind to the same receptors in the brain as heroin but do not produce the same effects. Synthetic antagonists, on the other hand, are designed to bind more strongly to the receptors and prevent heroin from binding at all. Both types of antagonists have been shown to be effective in reducing heroin use and preventing relapse. However, they are not without side effects, and they must be used in combination with other treatments to be most effective.

Aversive therapy is a treatment for substance abuse that uses negative reinforcement to discourage drug use. Aversive therapy can take many forms, but all methods share the goal of making drug use unpleasant or uncomfortable in order to decrease the likelihood of relapse. A common form of aversive therapy for heroin and opioid addiction is the administration of naloxone, a medication that blocks the effects of opioids. Naloxone is typically given in combination with a potent opiate such as buprenorphine, and the two drugs are alternated on a daily basis. When used as part of a comprehensive treatment plan, aversive therapy can be an effective tool for helping people overcome addiction.

Though vaccines are most commonly associated with protecting against communicable diseases, there is a growing body of research examining their potential to treat a wide variety of conditions, including addiction. A vaccine against addiction would work by creating antibodies that bind to and neutralize drug molecules, preventing them from reaching the brain and producing the reinforcing effects that maintain addictive behaviors. Several attempts have been made to develop a vaccine for opioid use disorder, and though none have yet been approved for human use, several show promise. One study found that a vaccine was effective in reducing drug-seeking behavior in rats, and another found that a vaccine was able to block the reinforcing effects of heroin in monkeys. These findings suggest that a vaccine could be an effective treatment for opioid use disorder, though further research is needed to confirm these results.

Summaries of Key Research

Bell and Strang (2020) summarize relevant literature on drug treatment for opioid addiction. In their review, they do not provide systematic analysis but simply cover the general area of the field. Their main points are that Opioid Use Disorder (OUD) is a chronic condition and that strong evidence exists indicating that medications like methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist) are effective for treating OUD. They describe how methadone and buprenorphine work by suppressing opioid withdrawal symptoms and attenuating the effects of other opioids. They also discuss how naltrexone inhibits the effects of opioid agonists. One point they emphasize is that the most significant evidence shows oral methadone has the greatest effectiveness. Studies on its use show that longer treatment using oral methadone typically results in the re-establishment of social connections for the patient and other positive outcomes. However, the authors note that treatments for OUD are often limited due to inadequate treatment recommendations from healthcare providers, propensity for relapse, and the potentially heightened risk of overdose upon ending treatment.

Bisaga et al. (2018) examined literature from the 1960s onward to evaluate research on antagonist therapy, particularly focusing on the evolution of treatment strategies for managing opioid withdrawal and the use of naltrexone. They note that newer practices involve extended-release naltrexone with agonist tapers and adjuvant medications. However, they also highlight the clinical challenges that remain, such as the need to manage withdrawal and ongoing addiction while the patient receives treatment. They point out that various clinical factors should be considered when providing individualized treatment, including the level of opioid abuse and patient comfort with naltrexone. Finally, the authors emphasize that most patients do not receive effective treatment for managing relapse.

Murphy (2020) conducted a retrospective analysis of 2018 data obtained through the National Survey on Drug Use and Health and the CDC WONDER Database in order to understand the value of OUD aversion for individuals ages 12 through 71, from their own perspective. The findings show that the economic consequences of addiction may be the best form of negative reinforcement therapy, and that this should be further explored by researchers in the field. Murphy (2020) relies on economic data from these sources for analysis and did not obtain any new primary data for the study.

Pantazis et al. (2021) focus on how pain triggers drive opioid use and explore sex differences among opioid abusers. Their main takeaway is that withdrawal symptoms arise when an individual stops taking opioids after extended use, and that any negative experience — such as anxiety — can trigger these symptoms. In response, individuals tend to seek out and consume opioids in order to relieve their discomfort, with no aversive therapy in place to counter this reinforcement. Their argument is that withdrawal itself is so aversive that addicts will return to the drug to avoid it. While drug use may initially relieve the uncomfortable symptoms of withdrawal, it ultimately leads to further drug use and addiction. The researchers therefore conclude that it is important to be aware of the potential role that environmental stimuli can play in promoting motivated opioid-seeking behavior.

The National Institutes of Health (NIH, 2022) reports on the state of anti-drug vaccines, explaining that a vaccine theoretically produces antibodies that bind to opioids and prevent them from crossing the blood-brain barrier. The first human test is set to use an oxycodone vaccine in a clinical facility with a small sample of participants. Researchers will be examining how long the vaccine remains effective and whether it might have clinical value.

Hwang et al. (2019) explore the most recent results of research on heroin vaccines with a view toward enhancing the vaccine's effectiveness. They examine in particular the protein Hsp70 and its role as an antigen and as a potential dual carrier-adjuvant. Their research suggests that this protein may serve as an effective mediator in blocking heroin's psychoactivity, and the findings appear to open new avenues for further research on anti-drug vaccines.

Purpose and Significance

As Murphy (2020) points out, the topic of treatment strategies is important to study because the costs of not addressing addiction and relapse are extremely high. The use of opioids and heroin has become a significant public health issue in recent years. As the NIH (2022) notes, over 2 million Americans suffer from addiction to these substances. While many factors contribute to this problem, one significant factor is the lack of effective treatment options. Currently, the main treatment strategies for opioid and heroin addiction are based on abstinence and harm reduction (Bisaga et al., 2018). However, neither of these approaches has been shown to be effective in the long term. As a result, there is a need for new treatment strategies that can help reduce the harmful effects of these substances.

The study of treatment strategies for opioid and heroin addiction is important because it can help identify new approaches that may be more effective in the long term, and because it can deepen our understanding of the factors that contribute to addiction. The treatment strategies examined by these researchers focus primarily on antagonist, aversion, and vaccine therapies, each of which has its own strengths and limitations.

Conclusion

Naltrexone is a medication that has been shown to be an effective treatment for opioid addiction. Unlike aversion therapy — which seeks to make the user feel sick when they take opioids — and anti-drug vaccines — which seek to produce antibodies that bind to drug molecules and prevent them from entering the brain — naltrexone works by blocking the effects of opioids at the receptor level. This makes it less likely that the user will experience the pleasurable effects of taking opioids, and therefore less likely that they will continue using them. Naltrexone has been shown to be more effective than other approaches in reducing both the frequency and intensity of opioid use, as well as the risk of relapse. Furthermore, naltrexone is generally well-tolerated and does not produce serious side effects. For these reasons, naltrexone should be considered the best current therapeutic approach for treating opioid addiction. However, naltrexone does not fully control for relapse, and addressing that challenge remains an important ongoing priority for the field.